[ad_1]
Cosentyx is the first biological product approved in China that specifically inhibits interleukin-17A (IL-17A), a fundamental cytokine involved in the inflammation of psoriasis (PsO), psoriatic arthritis (PsA ) and ankylosing spondylitis (AS).
Novartis, world leader in immuno-dermatology and rheumatology, announced that the NMPA of the China Health Authority approved Cosentyx (secukinumab), first inhibitor of interleukin-17A (IL-17A) for the treatment of plaque psoriasis moderate to severe adult patients candidates for systemic therapy or phototherapy.
"Reinventing the management of psoriatic disease to give patients the opportunity to live without the burden of psoriasis is a key goal for us," said Paul Hudson, CEO of Novartis Pharmaceuticals. "With Cosentyx, we are offering a new treatment to doctors and psoriasis patients in China, who can act in less than 3 weeks, has demonstrated sustainable safety for more than 200,000 patients worldwide and can provide what doctors and patients are looking for. "
"We are pleased to offer Cosentyx to doctors and patients in China." Cosentyx's approval marked the beginning of a new era of psoriasis treatment, redefining the goal of treatment by making it possible for Clear or almost clear skin.The introduction of Cosentyx is expected to bring exceptional clinical benefit Many psoriasis patients in China are improving their quality of life, "said Ingrid Zhang, president of Novartis Pharmaceuticals China.
Cosentyx is the first and only fully human treatment for psoriasis, which specifically inhibits IL-17A. Cosentyx is characterized by long-lasting safety, fast, long-lasting control and a placebo-like injection site reaction. A recent phase III study in patients in China showed that 80.9% of Cosentyx 300 mg-treated patients administered every 4 weeks (after 4 weeks) after loading had clear or nearly clear skin First 12 weeks of treatment and close to 9/10 patients after 16 weeks (87.0%).
"The average age of psoriasis in China is about 30 years, and many of the moderately to severely severe patients are in the prime of life.This population plays an irreplaceable role in their family, their workplace and society.Thus, a high-efficiency treatment, We are seeking a good safety profile and long-term control of diseases to help patients regain normal life and work, "said the Professor Jianzhong Zhang, former president of the Chinese Dermatology Society of the Chinese Medical Association. "The positive data on China presented recently give us hope for the clinical use of secukinumab in China .I hope to see Chinese patients benefit from this innovative treatment and be relieved of their burden of disease."
Currently, in China, more than 6 million people live with psoriasis, including mild, moderate and severe forms of the disease. Psoriasis is a debilitating disease that affects the quality of life of patients, both physically and emotionally. Real data from the United States has shown that 2/3 of biologically eligible patients have RP or other persistent manifestations of psoriasis in the nails, scalp and palmoplantar areas.
Cosentyx relies on strong clinical evidence, including 5-year phase III extension studies on RPO, PSA and SA, as well as specific studies on outbreaks. persistent psoriasis, especially on the nails, scalp and palmoplantar regions, dealing with different aspects of psoriatic disease. Today, more than 200,000 patients worldwide have been treated with Cosentyx since its launch.
[ad_2]
Source link
